Immunome Financial Statements
NASDAQ: IMNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunome revenue and earnings
In fiscal 2025, Immunome generated $6.9 million in revenue, down 23.2% from fiscal 2024, its first annual decline since 2024. Immunome reported a net loss of $212.4 million, compared with a loss of $293.0 million a year earlier. Operating margin was -3228.8%.
Diluted earnings per share came in at -$2.43.
Summary generated from market data by MetaCap's automated system. Methodology
Immunome income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Revenue | 6.94M | 9.04M | 14.02M | — | — | — | — |
| Revenue growth (YoY) | -23.23% | -35.50% | — | — | — | — | — |
| Operating Expenses | 231.05M | 314.84M | 123.55M | 36.90M | 25.20M | 12.26M | 10.35M |
| Research & Development | 177.29M | 129.54M | 23.09M | 23.27M | 14.11M | 7.49M | 8.82M |
| Operating Income | -224.11M | -305.80M | -109.53M | -36.90M | -25.20M | -12.26M | -10.35M |
| Interest Expense | — | — | — | — | — | 21.00K | 46.00K |
| Other Income (Expense) | — | — | — | 5.00K | 493.00K | -5.58M | — |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -212.39M | -292.96M | -106.81M | -36.90M | -24.71M | -17.84M | -10.44M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| EPS (Basic) | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 | -5.26 | -9.55 |
| EPS (Diluted) | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 | -5.26 | -9.55 |
| Shares Outstanding (Basic) | 87.35M | 58.64M | 19.84M | 12.13M | 11.54M | 3.39M | 1.09M |
| Shares Outstanding (Diluted) | 87.35M | 58.64M | 19.84M | 12.13M | 11.54M | 3.39M | 1.09M |
| EBITDA | -221.65M | -304.23M | -109.07M | -36.48M | -24.45M | -11.51M | -9.73M |
| Operating Margin | -3228.83% | -3382.37% | -781.35% | — | — | — | — |
| Net Margin | -3059.99% | -3240.38% | -761.92% | — | — | — | — |
This table shows 7 annual periods of Immunome's income statement, from FY 2025 back to FY 2019, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow IMNM's reporting calendar. What is a income statement?